Orgenesis Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Orgenesis Inc. (Nasdaq: ORGS) develops and commercializes cell and gene therapies through its proprietary POCare platform, which enables decentralized, point-of-care production of licensed POCare therapeutics including autologous cell-based immunotherapies, metabolic disease treatments, anti-viral therapies, and tissue regeneration products; the platform encompasses closed automated POCare technology systems, Octomera mobile processing units and labs (OMPULs), contract development and manufacturing organization (CDMO) services, regulatory support, pre-clinical studies, GMP process translation, hospital services, and distributed cell processing across a global POCare Network of research institutes, hospitals, and biotech partners. Founded in 2008 and headquartered in Germantown, Maryland, the company operates subsidiaries in Israel, Belgium, and South Korea, targeting biotech firms, academia, healthcare providers, and patients with rare neurological disorders, genetic metabolic diseases, autoimmune conditions, and oncology needs worldwide. Recent developments include regaining 100% ownership of its Octomera CGT processing subsidiary in 2024, forming a strategic asset purchase and co-marketing partnership with Germfree to manufacture, distribute, and service OMPULs globally, securing $2.3 million in investor funding and over $50 million in potential grants, converting $16 million of debt to equity, and acquiring Neurocords assets in March 2025 to expand regenerative therapies for spinal cord injuries.
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio
Critical Contrast: UCB (OTCMKTS:UCBJF) versus Orgenesis (NASDAQ:ORGS)
Orgenesis (NASDAQ:ORGS) Stock Price Up 300% – Time to Buy?
Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS)
Statera Biopharma (NASDAQ:STAB) vs. Orgenesis (NASDAQ:ORGS) Financial Contrast
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
Orgenesis Provides Business Update for the First Quarter of 2024
Orgenesis Provides Year End Business Update
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
Orgenesis Inc. Announces $2.3 Million Private Placement
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
Orgenesis Provides Business Update for the Third Quarter of 2023
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering